Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.

Last week, Moderna said that the initial refusal from the FDA was inconsistent with previous feedback from the agency.

Moderna announced that the FDA agreed to review its application for a mRNA-based flu vaccine after it agreed to further study in older adults.

Moderna's mRNA-1010 flu vaccine for older adults could be made available by the end of 2026, the pharmaceutical company ...

Moderna's stock surges after the FDA said it would review the biotech's flu vaccine candidate, a week after it had refused to do so. Shares of Moderna surged Wednesday after the drugmaker got health ...

Moderna said the move is inconsistent with previous feedback from the FDA on the experimental influenza shot, called mRNA-1010.

Rabies vaccination before you travel can reduce the need for this post-exposure prophylaxis or can simplify your treatment if ...

COMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna's fourth vaccine to receive a positive C ...

Ana Santos Rutschman does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...

The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday. The news is the ...

February 21, 2026 - Next generation influenza vaccines that provide broader and longer-lasting protection than existing seasonal vaccines, could play a vital role in reducing the global burden of ...

Moderna expects international markets to drive 2026 growth CEO Bancel warns U.S. regulatory uncertainty may hinder domestic access to new therapies Shares rise over 10% after reporting results Feb 13 ...